Abeona Therapeutics Inc.
NCM: ABEOLive Quote
📈 ZcoreAI Score
Our AI model analyzes Abeona Therapeutics Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ABEO Z-Score →About Abeona Therapeutics Inc.
Healthcare
Biotechnology
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
📊 Fundamental Analysis
Abeona Therapeutics Inc. demonstrates exceptional profitability, with a profit margin of 1223.1%.
Return on Equity (ROE) is 70.0%, which reflects exceptional capital efficiency.
At a current price of $4.91, ABEO currently sits at the 26th percentile of its 52-week range (Range: $4.00 - $7.54).
💰 Valuation Insight
ABEO trades at a 80.6% discount (PE: 4.86), which may represent a value opportunity given the sector average of 25.00. Analysts anticipate some earnings pressure, with a higher forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
✅
Return on Equity
Excellent
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$280.11M
Trailing P/E
4.86
Forward P/E
20.46
Beta (5Y)
1.21
52W High
$7.54
52W Low
$4.00
Avg Volume
1.28M
Day High
Day Low